NYSE:DNA Ginkgo Bioworks (DNA) Stock Price, News & Analysis $12.95 +1.61 (+14.20%) Closing price 10/9/2026 03:59 PM EasternExtended Trading$13.02 +0.07 (+0.54%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ginkgo Bioworks Stock (NYSE:DNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ginkgo Bioworks alerts:Sign Up Key Stats Today's Range$11.48▼$13.5650-Day Range$6.51▼$15.0652-Week Range$5.37▼$18.22Volume4.51 million shsAverage Volume3.41 million shsMarket Capitalization$872.05 millionP/E RatioN/ADividend YieldN/APrice Target$6.33Consensus RatingReduce Company Overview Ginkgo Bioworks, Inc. is a biotechnology company that develops biological engineering technologies and services. Its platform is designed to help customers program cells and microorganisms to produce products or perform functions for applications in areas such as pharmaceuticals, agriculture, food, chemicals and materials. The company combines biological research, laboratory automation, genetic engineering, data analysis and software through its cell-programming platform and foundry operations. Ginkgo also provides biosecurity and biological monitoring services, including offerings intended to help detect and analyze biological threats and support public-health preparedness. Ginkgo was founded in 2008 by a group that included Jason Kelly, Reshma Shetty, Barry Canton, Austin Che and Tom Knight. The company is headquartered in Boston and works with organizations in the United States and internationally. Jason Kelly is a co-founder and has served as the company’s chief executive officer.AI Generated. May Contain Errors. Read More Ginkgo Bioworks Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreDNA MarketRank™: Ginkgo Bioworks scored higher than 27% of companies evaluated by MarketBeat, and ranked 776th out of 883 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.6 / 5Analyst RatingReduce Consensus RatingGinkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 2 sell ratings.Downside RiskGinkgo Bioworks has a consensus price target of $6.33, representing about 51.1% downside from its current price of $12.95.Amount of Analyst CoverageGinkgo Bioworks has only been the subject of 4 research reports in the past 90 days.Read more about Ginkgo Bioworks' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ginkgo Bioworks are expected to grow in the coming year, from ($3.20) to ($2.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ginkgo Bioworks is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ginkgo Bioworks is -2.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGinkgo Bioworks has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Ginkgo Bioworks' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.44% of the float of Ginkgo Bioworks has been sold short.Short Interest Ratio / Days to CoverGinkgo Bioworks has a short interest ratio ("days to cover") of 2.67, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ginkgo Bioworks has recently increased by 2.08%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGinkgo Bioworks does not currently pay a dividend.Dividend GrowthGinkgo Bioworks does not have a long track record of dividend growth. News and Social Media3.4 / 5News Sentiment0.38 News SentimentGinkgo Bioworks has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Ginkgo Bioworks this week, compared to 3 articles on an average week.Search Interest5 people have searched for DNA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows9 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 125% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $73,748.00 in company stock.Percentage Held by Insiders12.69% of the stock of Ginkgo Bioworks is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ginkgo Bioworks' insider trading history. Receive DNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ginkgo Bioworks and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNA Stock News HeadlinesGinkgo Bioworks (NYSE:DNA) Shares Gap Down Following Insider SellingOctober 10 at 1:21 AM | americanbankingnews.comAraceli Biosciences und Ginkgo Bioworks ermöglichen die zelluläre Bildgebung in großem Maßstab für das „Lab-in-the-Loop"-System von NebulaOctober 8 at 12:00 AM | prnewswire.comAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly 80% afterward. He also called the housing crisis and the collapse of Bear Stearns and Lehman Brothers before they happened. Now Tilson says the day after this year's midterm elections, America enters a period of economic change unlike anything seen in decades - and most investors are unprepared.October 10 at 1:00 AM | Stansberry Research (Ad)Ginkgo Bioworks to Provide Lab Access to NSF X-Labs ResearchersOctober 8 at 10:11 PM | marketscreener.comMGinkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers, Contributing Cloud Lab Time and Protein Testing Services to $1.5 Billion Breakthrough Science ProgramOctober 8 at 5:00 PM | businesswire.comInsider Selling: Ginkgo Bioworks (NYSE:DNA) Insider Sells 2,403 Shares of Company StockOctober 8 at 6:37 AM | insidertrades.comAraceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-LoopOctober 8 at 6:00 AM | prnewswire.comGinkgo Bioworks (NYSE:DNA) Director Sells 5,000 SharesSeptember 17, 2026 | insidertrades.comSee More Headlines DNA Stock Analysis - Frequently Asked Questions How have DNA shares performed this year? Ginkgo Bioworks' stock was trading at $8.27 at the start of the year. Since then, DNA stock has increased by 56.6% and is now trading at $12.95. How were Ginkgo Bioworks' earnings last quarter? Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) issued its earnings results on Wednesday, August, 5th. The company reported ($0.75) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.15. The company earned $20.16 million during the quarter, compared to analyst estimates of $24.05 million. Ginkgo Bioworks had a negative net margin of 259.96% and a negative trailing twelve-month return on equity of 60.27%. Read the conference call transcript. How do I buy shares of Ginkgo Bioworks? Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ginkgo Bioworks own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), Compass Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings8/05/2026Today10/10/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, DNA's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNYSE:DNA CIK1830214 Webwww.ginkgobioworks.com Phone877-442-5362FaxN/AEmployees485Year Founded2020Price Target and Rating Average Price Target for Ginkgo Bioworks$6.33 High Price Target$9.00 Low Price Target$5.00 Potential Upside/Downside-51.1%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($5.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$312.76 million Net Margins-259.96% Pretax Margin-277.33% Return on Equity-60.27% Return on Assets-26.88% Debt Debt-to-Equity RatioN/A Current Ratio4.57 Quick Ratio4.57 Sales & Book Value Annual Sales$170.15 million Price / Sales5.13 Cash FlowN/A Price / Cash FlowN/A Book Value$8.74 per share Price / Book1.48Miscellaneous Outstanding Shares67,340,000Free Float58,795,000Market Cap$872.05 million OptionableOptionable Beta1.79 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NYSE:DNA) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ginkgo Bioworks Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ginkgo Bioworks With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
